A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder - Nasser, Azmi; Hull, Joseph T.; Chaturvedi, Soumya A.; Liranso, Tesfaye; Odebo, Oyinkansola; Kosheleff, Alisa R.; Fry, Nicholas; Cutler, Andrew J.; Rubin, Jonathan; Schwabe, Stefan; Childress, Ann (CNS drugs, 2022)
Keywords: Adult; Adults; Adverse events; Anxiety disorders; Appetite loss; Attention Deficit Disorder with Hyperactivity - diagnosis; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention deficit hyperactivity disorder; Capsules - therapeutic use; Central Nervous System Stimulants - therapeutic use; Child; Children; Clinical trials; Delayed-Action Preparations - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Drug dosages; Executive function; FDA approval; Humans; Hyperactivity; Impulsive behavior; Impulsivity; Insomnia; Medicine; Medicine & Public Health; Mental disorders; Nausea; NCT; NCT04016779; Neurodevelopmental disorders; Neurology; Neurosciences; Original; Original Research Article; Pediatrics; Pharmacotherapy; Placebos; Psychiatry; Psychopharmacology; Safety; Sleep disorders; Statistical analysis; Teenagers; Treatment Outcome; Viloxazine - therapeutic use; United States--US